New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
16:02 EDTGEVASynageva announces publication of sebelipase alfa study
Synageva BioPharma announced publication of the 12-week Phase I/II extension study data of sebelipase alfa in adults with lysosomal acid lipase deficiency in the online version and an upcoming print edition of Hepatology. Nine adults with LAL Deficiency were enrolled in the Phase I/II trial. After completing the initial portion of the Phase I/II trial, patients were allowed to continue treatment with sebelipase alfa as part of a long-term, open-label extension study. In the extension study, patients received four once-weekly infusions of sebelipase alfa and then transitioned to every other week infusions of sebelipase alfa. Eight of nine patients enrolled in the extension study. Data published in Hepatology were derived from the seven patients who completed the first 12 weeks of dosing in the extension study. Sebelipase alfa was well tolerated throughout the initial 12 weeks of the extension study, the company said.
News For GEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 16, 2014
10:01 EDTGEVAOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:53 EDTGEVASynageva initiated with a Buy at SunTrust
Target $117.
October 8, 2014
10:06 EDTGEVASynageva announces sebelipase alfa Phase 3 study data presentation
Synageva BioPharma announced that data from its Phase 3, global clinical study evaluating sebelipase alfa in children and adults with LAL Deficiency has been selected for oral presentation during the late-breaking session at The Liver Meeting, the 65th Annual Meeting of the American Association for the Study of Liver Diseases, being held November 7-11. The data will be presented during the late-breaking oral session on November 10.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use